REG - Eden Research plc - Thymolflex EPA approval

Eden ResearchAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260402:nRSB1487Za&default-theme=true

RNS Number : 1487Z  Eden Research plc  02 April 2026

As the information in this release pertains to EDEN RESEARCH PLC, this
announcement is deemed to constitute inside information as stipulated under
the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014
(the "UK MAR"), which is part of UK law by virtue of the European Union
(Withdrawal) Act 2018. The information is disclosed in accordance with the
Company's obligations under Article 17 of the UK MAR. Upon the publication of
this announcement, this inside information is now considered to be in the
public domain.

 

2 April 2026

 

 

Eden Research Plc

("Eden" or "Company")

 

Thymolflex® EPA approval

 

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and
biocontrol technologies, is pleased to announce that the Company's partner,
Véto-pharma, has received regulatory approval from the US Environmental
Protection Agency ("EPA") for Thymolflex® for use in integrated Varroa
management. Thymoflex® is a thymol-based treatment used in bee health to
control Varroa destructor, an external parasitic mite that attacks and feeds
on honey bees. This approval follows an announced agreement, signed by the
Company in April 2025, to supply Véto-pharma with thymol for use in bee care
products.

 

Supporting integrated Varroa management strategies

 

Varroa destructor remains one of the most significant threats to honey bee
health worldwide. As resistance concerns increase and environmental conditions
become more unpredictable, beekeepers need multiple authorised tools that can
be adapted to different colony conditions and management systems.

 

Thymoflex® is based on thymol, a well-known active substance of natural
origin, widely used by beekeepers as part of integrated pest management (IPM)
programs.

 

Thymoflex® is a ready-to-use thymol gel designed for straightforward handling
and application in the apiary. The product allows for a controlled release of
thymol within the hive, contributing to effective mite control when used
according to label directions. Its formulation aims to combine ease of use,
consistency, and colony safety, making it suitable for professional beekeeping
operations.

 

By expanding access to thymol-based solutions, Thymoflex® offers beekeepers
an additional option to:

·      A treatment based on a naturally derived active substance

·      Flexible use within the beekeeping season, according to label
instructions

·      Reduce reliance on a single mode of action

·      Proven efficacy against varroa, including in the presence of
brood

·      Compatibility with treatment rotation programs, helping to manage
resistance risks

·      Enhance grooming behaviour and overall hygienic responses in
honey bee colonies.

 

The gel formulation enables a homogeneous diffusion of thymol within the hive,
contributing to colony safety when used according to label directions.

 

Availability

 

Thymoflex® has received EPA federal approval and will be made available to
beekeepers in the United States in accordance with individual state
registrations.

 

More information about Thymoflex® will be available soon on the Véto-pharma
website: https://www.veto-pharma.com (https://www.veto-pharma.com)

 

A long-standing commitment to honey bee health

Honeybee health is affected by multiple factors, including climate change,
habitat loss, nutritional stress, pesticide exposure, and pathogens, among
which varroa plays a central role. Addressing these challenges requires
robust, flexible, and science-based solutions.

 

For more than 25 years, Véto-pharma has focused exclusively on honey bee
health, developing and manufacturing products designed to support beekeepers
worldwide in protecting their colonies and securing the future of pollination.

 

Sean Smith, CEO of Eden Research, commented:

 

"We are delighted to be able to play such a key role in the delivery of vital
care products to keep bee populations thriving. Our partnership with
Véto-pharma is representative of our commitment to diversifying our business
model and revenue streams by applying our sustainable chemical technology to
other sectors beyond arable agriculture."

 

-- ENDS --

 

For further information, contact:

 

 Eden Research plc                                                       www.edenresearch.com (http://www.edenresearch.com/)
 Sean Smith                                                              01285 359 555

Alex Abrey

 Cavendish Capital Markets Limited (Nominated advisor and joint broker)
 Giles Balleny / Elysia Bough (Corporate Finance)                        020 7220 0500

 Harriet Ward (Corporate Broking)

Dale Bellis (Sales)

 Oberon Capital (Joint Broker)                                           020 3179 5300
 Nick Lovering

 Mike Seabrook

 Adam Pollock

 Hawthorn Advisors (Financial PR)
 Jamie Plotnek                                                           eden@hawthornadvisors.com (mailto:eden@hawthornadvisors.com)

 

Notes to Editors:

 

About Eden Research

 

Eden Research is the only UK-listed company focused on biopesticides for
sustainable agriculture. It develops and supplies innovative biopesticide
products and natural microencapsulation technologies to the global crop
protection, animal health and consumer products industries.

 

For more information about Eden, visit:  www.edenresearch.com
(http://www.edenresearch.com/) .

 

Follow Eden on LinkedIn (https://www.linkedin.com/company/eden-research-plc/)
, Twitter (https://twitter.com/edenresearch)  and YouTube
(https://www.youtube.com/@edenresearch580) .

About Véto-pharma

Founded in 1982, Véto-pharma is a veterinary pharmaceutical laboratory
dedicated to honey bee health. The company is recognised globally for its
expertise, innovation, and high-quality products developed and manufactured in
France.

For more information about Véto-pharma, visit: https://www.veto-pharma.com
(https://www.veto-pharma.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  REAIBMRTMTMMBAF



            Copyright 2019 Regulatory News Service, all rights reserved